Stock Track | GENSCRIPT BIO Soars 6.61% Intraday on Strong CARVYKTI Sales and Upcoming Interim Results

Stock Track

08/10

GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor optimism.

The move came after the company's associate, Legend Biotech, reported robust second-quarter net trade sales for its CARVYKTI therapy of approximately $657 million, marking a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Additionally, GENSCRIPT BIO is set to hold a board meeting on August 15 to review and approve its interim results for the six months ended June 30, with the potential for an interim dividend adding to market enthusiasm.

The broader CXO sector also provided a tailwind, with peers like WuXi AppTec reporting strong adjusted net profit growth of about 89% year-over-year for the first half, lifting overall industry sentiment. These multiple catalysts combined to drive the stock's sharp intraday advance.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1135232444"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135232444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135232444?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135232444","market":"sg","top_or_hot":-1,"title":"Stock Track | GENSCRIPT BIO Soars 6.61% Intraday on Strong CARVYKTI Sales and Upcoming Interim Results","media":"Stock Track","content":"<p>GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor optimism.</p><p>The move came after the company's associate, Legend Biotech, reported robust second-quarter net trade sales for its CARVYKTI therapy of approximately $657 million, marking a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Additionally, GENSCRIPT BIO is set to hold a board meeting on August 15 to review and approve its interim results for the six months ended June 30, with the potential for an interim dividend adding to market enthusiasm.</p><p>The broader CXO sector also provided a tailwind, with peers like WuXi AppTec reporting strong adjusted net profit growth of about 89% year-over-year for the first half, lifting overall industry sentiment. These multiple catalysts combined to drive the stock's sharp intraday advance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GENSCRIPT BIO Soars 6.61% Intraday on Strong CARVYKTI Sales and Upcoming Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GENSCRIPT BIO Soars 6.61% Intraday on Strong CARVYKTI Sales and Upcoming Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-10 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor optimism.</p><p>The move came after the company's associate, Legend Biotech, reported robust second-quarter net trade sales for its CARVYKTI therapy of approximately $657 million, marking a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Additionally, GENSCRIPT BIO is set to hold a board meeting on August 15 to review and approve its interim results for the six months ended June 30, with the potential for an interim dividend adding to market enthusiasm.</p><p>The broader CXO sector also provided a tailwind, with peers like WuXi AppTec reporting strong adjusted net profit growth of about 89% year-over-year for the first half, lifting overall industry sentiment. These multiple catalysts combined to drive the stock's sharp intraday advance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1135232444","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135232444","pubTimestamp":1786325673,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"股票跟踪 | 由于汽车销售强劲和即将公布的中期业绩，金斯瑞生物盘中飙升 6.61%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor optimism.The move came after the company's associate, Legend Biotech, reported robust second-quarter net trade sales for its CARVYKTI therapy of approximately $657 million, marking a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Additionally, GENSCRIPT BIO is set to hold a board meeting on August 15 to review and approve its interim results for the six months ended June 30, with the potential for an interim dividend adding to market enthusiasm.The broader CXO sector also provided a tailwind, with peers like WuXi AppTec reporting strong adjusted net profit growth of about 89% year-over-year for the first half, lifting overall industry sentiment. These multiple catalysts combined to drive the stock's sharp intraday advance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}